FreeTheAI

Johnson & Johnson Shares Drop Despite Higher Full-Year Profit Forecast

BearishMedium impact
JNJ$248.61 −5.73%

Shares of Johnson & Johnson (NYSE:JNJ) declined after the company released its quarterly financial results. Although the business raised its 2026 adjusted earnings guidance midpoint to $11.10 per share, the stock fell over 5%. Total sales for the quarter reached $25.40 billion, but adjusted earnings per share fell 7.5% from the prior year to $2.59. Net reported earnings dropped to $0.09 per share, impacted by proposed talc litigation settlement charges and transaction-related expenses.

The negative stock reaction highlights investor anxiety over narrowing profit margins and uneven sales growth. While revenue in the Innovative Medicine division grew 7.7%, the MedTech unit managed only a 2.5% increase. The disparity between steady pharmaceutical growth and weaker device demand made it difficult for investors to look past the drop in quarterly adjusted profits, despite the slight boost to full-year earnings expectations.

Looking ahead, market participants will be watching for signs of stronger growth in the medical technology division and better profit conversion across all business lines. Investors will also follow progress on resolving outstanding litigation charges to see if the company can re-establish earnings momentum.

Key points

  • Johnson & Johnson raised the midpoint of its 2026 adjusted earnings guidance to $11.10 per share.
  • Quarterly sales reached $25.40 billion, supported by 7.7% growth in the Innovative Medicine division.
  • Adjusted earnings per share declined 7.5% year-over-year to $2.59.
  • Reported earnings per share fell to $0.09 due to talc settlement charges and transaction items.
  • MedTech segment sales expanded by 2.5% during the period.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

Why did Johnson & Johnson stock drop after earnings?

Shares fell because quarterly adjusted earnings dropped 7.5% year-over-year and MedTech segment growth remained weak at 2.5%, overshadowing a small increase in full-year guidance.

What were Johnson & Johnson's revenue and earnings figures?

Quarterly revenue was $25.40 billion with adjusted earnings of $2.59 per share. Reported earnings were $0.09 per share, impacted by talc-related legal expenses and transaction charges.

Did Johnson & Johnson change its financial guidance for 2026?

Yes, Johnson & Johnson raised the midpoint of its full-year 2026 adjusted earnings forecast by six cents to $11.10 per share.